Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY3502970 With and Without Clarithromycin in Healthy Participants
NCT05469126Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity, Area Under the Concentration Time Curve From Time Zero to Time T and 1 more. Started Aug 2022; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05469126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469126.